Skip to main content
AmigoFish

Fragile X at a turning point: Breaking through the clinical bottleneck

From BioSpace · · 19 min

This plays from the publisher's own server. We do not host a copy.

Open at the source

Not rated yet

Description

In this episode of Denatured, you’ll hear from Hilary Rosselot, executive director at the National Fragile X Foundation and Jordi Fàbrega, co-founder & CEO at CONNECTA Therapeutics. From trial endpoints and placebo effects to neuroplasticity modulation, we explore what it will take to build a sustainable path to the first approved therapy.

Host

Jennifer C. Smith-Parker (https://www.linkedin.com/in/jennifersmithparker/), Director of Insights, BioSpace

Guests

Hilary Rosselot (https://www.linkedin.com/in/hilary-rosselot/), Executive Director, National Fragile X Foundation

Jordi Fàbrega (https://www.linkedin.com/in/fabregajordi/), Co-Founder & CEO, CONNECTA Therapeutics

Disclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.

Back to BioSpace · Report a problem